| 12435155 |
CD137 binding molecules and uses thereof |
Alexey Yevgenyevich BEREZHNOY, Gundo Diedrich, Ezio Bonvini, Kalpana Shah |
2025-10-07 |
|
| 11942149 |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
Liqin Liu, Chia-Ying Kao Lam, Gundo Diedrich, Leslie S. Johnson, Ezio Bonvini |
2024-03-26 |
$14,583,000 |
| 11858991 |
LAG-3-binding molecules and methods of use thereof |
Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Ezio Bonvini +1 more |
2024-01-02 |
$11,568,000 |
| 11840571 |
Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 |
Leslie S. Johnson, Gurunadh Reddy Chichili, Kalpana Shah, Ross La Motte-Mohs, Ezio Bonvini +1 more |
2023-12-12 |
$10,306,000 |
| 11820818 |
Multi-chain polypeptide-containing tri-specific binding molecules |
Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam +4 more |
2023-11-21 |
$8,850,000 |
| 11802164 |
Methods and compositions for diagnosing and treating diseases |
Steve Ruben, Tao He, Candy LEE, Karen VAN ORDEN |
2023-10-31 |
|
| 11697684 |
Tri-specific binding molecules that specifically bind to multiple cancer antigens |
Ezio Bonvini, Jonathan Li, Leslie S. Johnson, Kalpana Shah |
2023-07-11 |
$6,512,000 |
| 11685781 |
Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
Ezio Bonvini, Ling Huang, Chia-Ying Kao Lam, Gurunadh Reddy Chichili, Ralph Alderson +1 more |
2023-06-27 |
|
| 11639386 |
Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof |
Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Liqin Liu, Scott Koenig |
2023-05-02 |
$10,664,000 |
| 11623959 |
PD-1-binding molecules and methods of use thereof |
Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Ezio Bonvini +1 more |
2023-04-11 |
$9,665,000 |
| 11459394 |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
Liqin Liu, Chia-Ying Kao Lam, Gundo Diedrich, Leslie S. Johnson, Ezio Bonvini |
2022-10-04 |
$2,042,000 |
| 11384149 |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
Leslie S. Johnson, Ling Huang, Kalpana Shah, Ezio Bonvini, Wei Chen |
2022-07-12 |
$4,382,000 |
| 11098119 |
Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof |
Ezio Bonvini, Leslie S. Johnson, Kalpana Shah, Ross La Motte-Mohs, Scott Koenig |
2021-08-24 |
$9,808,000 |
| 11072653 |
LAG-3-binding molecules and methods of use thereof |
Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Ezio Bonvini +1 more |
2021-07-27 |
$22,267,000 |
| 10954301 |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
Leslie S. Johnson, Gurunadh Reddy Chichili, Kalpana Shah, Ross La Motte-Mohs, Ezio Bonvini +1 more |
2021-03-23 |
$115,266,000 |
| 10858430 |
Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof |
Jonathan Li, Francine Zhifen Chen, Leslie S. Johnson, Kalpana Shah, Ezio Bonvini |
2020-12-08 |
$76,098,000 |
| 10787521 |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof |
Ezio Bonvini, Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Ralph Alderson |
2020-09-29 |
$80,950,000 |
| 10730945 |
Antibodies reactive with B7-H3 and users thereof |
Leslie S. Johnson, Ling Huang, Deryk T. Loo, Francine Zhifen Chen |
2020-08-04 |
$42,462,000 |
| 10683364 |
Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
Leslie S. Johnson, Ling Huang, Deryk T. Loo, Francine Zhifen Chen |
2020-06-16 |
$66,072,000 |
| 10647768 |
Multi-chain polypeptide-containing tri-specific binding molecules |
Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam +4 more |
2020-05-12 |
$75,281,000 |
| 10633440 |
Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens |
Ezio Bonvini, Jonathan Li, Leslie S. Johnson, Kalpana Shah |
2020-04-28 |
$2,718,000 |
| 10633443 |
Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof |
Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Liqin Liu, Scott Koenig |
2020-04-28 |
$2,718,000 |
| 10577422 |
PD-1-binding molecules and methods of use thereof |
Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Ezio Bonvini +1 more |
2020-03-03 |
$5,206,000 |
| 10501552 |
Multivalent molecules comprising DR5-binding domains |
Leslie S. Johnson, Jonathan Li, Kalpana Shah |
2019-12-10 |
$16,608,000 |
| 10344092 |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
Leslie S. Johnson, Ling Huang, Kalpana Shah, Ezio Bonvini, Wei Chen |
2019-07-09 |
$26,518,000 |
